Contact Us

N1-Methylpseudouridine-5'-Triphosphate - (N-1081)

N1-Methylpseudouridine-5'-Triphosphate, N1meΨTP, m1ΨTP, 1-Methyl-PseudoUridine Phosphoramidite, N1-Methyl-Pseudouridine-5'-Triphosphate
In stock
Product SKU Unit Size Price Qty
N-1081-1 1 µmole
N-1081-5 5 µmole
N-1081-10 10 µmole
N-1081-100 100 µmole

N1-Methylpseudouridine-5'-Triphosphate, sodium salt, is a modified NTP for incorporation into messenger RNAs (mRNA) using T7 RNA Polymerase. Incorporation of N1-Methylpseudouridine can reduce the immunogenicity of the resulting mRNA. 

To learn more about TriLink's N1-Methylpseudouridine, visit

Product details
Catalog No N-1081
Purity ≥99% by AX-HPLC
Extinction Coefficient 8,877 Lmol-1cm-1 at 271 nm
Molecular Formula C10H17N2O15P3 (free acid)
Molecular Weight 498.10 g/mole (free acid)
Salt Form Na+
Concentration 100 mM
Buffer H2O
Recommended Storage -20°C or below
Other Name(s) N1-Methylpseudouridine-5'-Triphosphate, N1meΨTP, m1ΨTP, 1-Methyl-PseudoUridine Phosphoramidite, N1-Methyl-Pseudouridine-5'-Triphosphate
Application In vitro Transcription
Backbone 5'-Triphosphate
Base Analog(s) Pseudouridine
Sugar Type(s) RNA
Nucleotide Category Base Modified RNA
Technical documents

Safety Data Sheet Look-up

Products faqs

A nucleoside contains only the base and the sugar (5'-OH) while a nucleotide refers to a nucleoside with phosphorylation on the sugar. This includes the phosphate groups on the 2', 3' or 5' ends.

We provide custom chemistry services. Please inquire about the feasibility of your desired nucleotide at

They are resuspended in water, pH 7.5±0.5.

A 1 µmole vial of 100 mM NTP contains 10 µL.

In general, we recommend equimolar amounts of nucleotides in IVT. The exact amounts depend on the IVT reagents and conditions. Please see our rNTP product inserts for IVT with CleanCap M6 and CleanCap AU analogs.

Yes, it can. Our product inserts have recommended ratios for small-scale IVT. If you would like to discuss it further, please contact us at or [email protected].

When stored properly at or below -20°C, NTPs should be stable for a few years. Upon first use, prepare aliquots to minimize freeze-thaw cycles and NTP degradation. 

Although NTPs are stable at room temperature for several days, they are shipped on wet or dry ice to ensure stability in the event of a transportation delay. Even if they have arrived thawed, they should still be good to use. If you have concerns or questions however, please contact us at or [email protected].

Each NTP is accompanied by a certificate of analysis with the methods of analysis, concentration, purity, identity, etc. Our GMP NTPs undergo further analyses for characterization, safety, and nuclease contamination.

We run 31P NMR, which reveals inorganic phosphate salt. Enzymologists usually have the most concern about this salt since it inhibits many polymerases.

Certificate of analysis

CoA search tool

Intellectual property

Products are for research use only, not for use in diagnostic or therapeutic procedures or for use in humans. Products are not for resale without express written permission from TriLink No license under any patent or other intellectual property right of TriLink or its licensors is granted or implied by the purchase unless otherwise provided in writing.

TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser's sole responsibility.

  1. Pardi, Norbert; Tuyishime, Steven; Muramatsu, Hiromi; Kariko, Katalin; Mui, Barbara L.; Tam, Ying K.; Madden, Thomas D.; Hope, Michael J.; Weissman, Drew . Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
  2. Pardi, Norbert; Parkhouse, Kaela; Kirkpatrick, Ericka; McMahon, Meagan; Zost, Seth J.; Mui, Barbara L.; Tam, Ying K.; Karikó, Katalin; Barbosa, Christopher J.; Madden, Thomas D.; Hope, Michael J.; Krammer, Florian; Hensley, Scott E.; Weissman, Drew . Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies.
  3. Tiwari, Pooja Munnilal; Vanover, Daryll; Lindsay, Kevin E.; Bawage, Swapnil Subhash; Kirschman, Jonathan L.; Bhosle, Sushma; Lifland, Aaron W.; Zurla, Chiara; Santangelo, Philip J. . Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection.
  4. Laczk . A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice
  5. Lockhart, JH;VanWye, J;Banerjee, R;Wickline, SA;Pan, H;Totary-Jain, H; . Self-assembled miRNA-switch nanoparticles target denuded regions and prevent restenosis
  6. Leppek, K;Byeon, GW;Kladwang, W;Wayment-Steele, HK;Kerr, CH;Xu, AF;Kim, DS;Topkar, VV;Choe, C;Rothschild, D;Tiu, GC;Wellington-Oguri, R;Fujii, K;Sharma, E;Watkins, AM;Nicol, JJ;Romano, J;Tunguz, B;Participants, E;Barna, M;Das, R; . Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
  7. Chen, PJ;Hussmann, JA;Yan, J;Knipping, F;Ravisankar, P;Chen, PF;Chen, C;Nelson, JW;Newby, GA;Sahin, M;Osborn, MJ;Weissman, JS;Adamson, B;Liu, DR; . Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
  8. Everton, E;Rizvi, F;Smith, AR;Beattie, M;Tam, Y;Pardi, N;Weissman, D;Gouon-Evans, V; . Transient yet Robust Expression of Proteins in the Mouse Liver via Intravenous Injection of Lipid Nanoparticle-encapsulated Nucleoside-modified mRNA
  9. Appelberg, S;John, L;Pardi, N;V . Nucleoside-modified mRNA vaccines protect IFNAR-/- mice against Crimean Congo hemorrhagic fever virus infection
  10. Matias, J;Kurokawa, C;Sajid, A;Narasimhan, S;Arora, G;Diktas, H;Lynn, GE;DePonte, K;Pardi, N;Valenzuela, JG;Weissman, D;Fikrig, E; . Tick immunity using mRNA, DNA and protein-based Salp14 delivery strategies
  11. Svitkin, YV;Gingras, AC;Sonenberg, N; . Membrane-dependent relief of translation elongation
  12. Parhiz, H;Brenner, JS;Patel, P;Papp, TE;Shahnawaz, H;Li, Q;Shi, R;Zamora, M;Yadegari, A;Marcos-Contreras, OA;Natesan, A;Pardi, N;Shuvaev, VV;Kiseleva, R;Myerson, J;Uhler, T;Riley, RS;Han, X;Mitchell, MJ;Lam, K;Heyes, J;Weissman, D;Muzykantov, V; . Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE)
  13. Whitley, J;Zwolinski, C;Denis, C;Maughan, M;Hayles, L;Clarke, D;Snare, M;Liao, H;Chiou, S;Marmura, T;Zoeller, H;Hudson, B;Peart, J;Johnson, M;Karlsson, A;Wang, Y;Nagle, C;Harris, C;Tonkin, D;Fraser, S;Capiz, L;Zeno, CL;Meli, Y;Martik, D;Ozaki, DA;Caparoni, A;Dickens, JE;Weissman, D;Saunders, KO;Haynes, BF;Sempowski, GD;Denny, TN;Johnson, MR; . Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials
  14. Aditham, A;Shi, H;Guo, J;Zeng, H;Zhou, Y;Wade, SD;Huang, J;Liu, J;Wang, X; . Chemically Modified mocRNAs for Highly Efficient Protein Expression in Mammalian Cells
  15. Ge, N;Sun, J;Liu, Z;Shu, J;Yan, H;Kou, Z;Wei, Y;Jin, X; . An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses
  16. Liu, W;Alameh, MG;Yang, JF;Xu, JR;Lin, PJC;Tam, YK; . Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approach
  17. Kaur, K;Hadas, Y;Kurian, AA;?ak, MM;Yoo, J;Mahmood, A;Girard, H;Komargodski, R;Io, T;Santini, MP;Sultana, N;Kabir Sharkar, MT;Magadum, A;Fargnoli, A;Yoon, S;Chepurko, E;Chepurko, V;Eliyahu, E;Pinto, D;Lebeche, D;Kovacic, JC;Hajjar, RJ;Rafii, S;Zangi, L; . Direct Reprogramming Induces Vascular Regeneration Post Muscle Ischemic Injury
  18. Nakanishi, H;Saito, H; . Purification of Specific Cell Populations Differentiated from Stem Cells Using MicroRNA-Responsive Synthetic Messenger RNAs
Show more